US29089Q1058 - Common Stock

Taking everything into account, **EBS** scores **2** out of 10 in our fundamental rating. **EBS** was compared to 597 industry peers in the **Biotechnology** industry. Both the profitability and financial health of **EBS** have multiple concerns. **EBS** has a expensive valuation and it also scores bad on growth.

In the past year **EBS** has reported negative net income.

With a **Return On Assets** value of **-51.87%**, **EBS** perfoms like the industry average, outperforming **46.78%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -51.87% | ||

ROE | -140.85% | ||

ROIC | N/A |

ROA(3y)3.9%

ROA(5y)3.37%

ROE(3y)6.7%

ROE(5y)6.26%

ROIC(3y)N/A

ROIC(5y)N/A

The **Gross Margin** of **EBS** (**29.46%**) is better than **77.12%** of its industry peers.

In the last couple of years the **Gross Margin** of **EBS** has declined.

The **Profit Margin** and **Operating Margin** are not available for **EBS** so they could not be analyzed.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 29.46% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-14.52%

GM growth 5Y-10.22%

Compared to 1 year ago, **EBS** has less shares outstanding

The number of shares outstanding for **EBS** has been increased compared to 5 years ago.

The debt/assets ratio for **EBS** is higher compared to a year ago.

With a **Debt to Equity ratio** value of **0.64**, **EBS** is not doing good in the industry: **77.12%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.64 | ||

Debt/FCF | N/A | ||

Altman-Z | 0.17 |

ROIC/WACCN/A

WACC3.75%

A Current Ratio of **1.09** indicates that **EBS** should not have too much problems paying its short term obligations.

The **Quick ratio** of **EBS** (**0.55**) is worse than **94.41%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.09 | ||

Quick Ratio | 0.55 |

The earnings per share for **EBS** have decreased strongly by **-296.86%** in the last year.

EPS 1Y (TTM)-296.86%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q62.2%

Revenue 1Y (TTM)-16.18%

Revenue growth 3Y0.35%

Revenue growth 5Y14.78%

Revenue growth Q2Q12.71%

The **Earnings Per Share** is expected to grow by **14.66%** on average over the next years. This is quite good.

EPS Next Y-96.04%

EPS Next 2Y63.96%

EPS Next 3Y36.81%

EPS Next 5Y14.66%

Revenue Next Year-3.1%

Revenue Next 2Y-0.09%

Revenue Next 3Y-2.01%

Revenue Next 5Y-7.06%

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

The **Price/Forward Earnings** ratio is **1.83**, which indicates a rather cheap valuation of **EBS**.

Based on the **Price/Forward Earnings** ratio, **EBS** is valued cheaply inside the industry as 99.49% of the companies are valued more expensively.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 1.83 |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

A more expensive valuation may be justified as **EBS**'s earnings are expected to grow with **36.81%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y63.96%

EPS Next 3Y36.81%

No dividends for **EBS**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**EMERGENT BIOSOLUTIONS INC**

NYSE:EBS (2/26/2024, 7:04:00 PM)

Premarket: 2.85 0 (0%)**2.85**

**+0.11 (+4.01%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap147.86M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 1.83 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -51.87% | ||

ROE | -140.85% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 29.46% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.67

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.64 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.09 | ||

Quick Ratio | 0.55 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-296.86%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-96.04%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-16.18%

Revenue growth 3Y0.35%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y